| Methods |
Randomised
Controlled
Trial
Single‐blind
Parallel group |
| Participants |
Country:
China
Mean age: 67
% Female: 55
Mean disease duration: 3 y
Duration: 16 wk
Number randomised: 150
5 groups with 50 per group
1) HA,
2) HA+low dose celecoxib (HALC),
3) HA + self‐
selected dose celecoxib (HASCC),
4) celecoxib (CEL), 5) Self‐selected celecoxib (SCC)
Inclusion: NR
Exclusion: NR
Baseline values:
WOMAC function
HA: 67.7,
HALC: 68.3,
HASCC: 70.2,
CEL: 71.3,
SCC: 70.4 |
| Interventions |
1) HA 2 ml (10mg/L) 5 weekly injections,
2) HA+low dose celecoxib (one course HA + 100 mg celecoxib once per day for 4 mth),
3) regular dose celecoxib 100 mg/day for 4 mth,
4) HA + self‐controlled dose of celecoxib
(one course of HA + celecoxib 100 mg bid) and dosage could be decreased once symptoms well controlled),
5) voluntary celecoxib 100 mg bid and dosage could be decreased with symptom control
Concurrent therapy: NR |
| Outcomes |
WOMAC physical function subscale‐‐‐‐‐‐‐‐‐‐‐
weekly dosage of celecoxib,
total dosage of celecoxib,
satisfaction level to the treatment protocol (bad, fine, good, and excellent)
Assessments at baseline, Wks 1,2,4,,8,10,12,14,16 |
| Notes |
Jadad's: 2/5
R‐1, B‐0, W‐1 |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
